ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.
Conditions: Multiple Myeloma in Relapse; Multiple Myeloma Progression; Multiple Myeloma Stage II; Multiple Myeloma Stage I; Multiple Myeloma With Failed Remission; Multiple Myeloma Stage III Interventions: Drug: Rivaroxaban; Drug: ASA Sponsors: Lawson Health Research Institute; The Ottawa Hospital; Dalhousie University; St. Boniface General Hospital Research Centre; McMaster University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials